TITLE

Review: Adding long-acting beta2-agonists to inhaled corticosteroids reduces asthma exacerbations more than adding antileukotrienes

AUTHOR(S)
Smith, Brian
PUB. DATE
July 2005
SOURCE
ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p46
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents information on a study related to long-acting beta2-agonists (LABAs) versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Randomized controlled trials comparing LABAs or leukotriene-receptor antagonists added to inhaled corticosteroids in patients with recurrent or persistent asthma. Patients were required to be on a stable dose of inhaled corticosteroid during a treatment period 28 days. The quality of the individual studies was assessed with the Jadad scale. The results of the study showed that the asthma exacerbations requiring systemic corticosteroids. Secondary outcomes included asthma control measures, adverse effects, and withdrawals.
ACCESSION #
18053703

 

Related Articles

  • Role of Leukotriene Receptor Antagonists in the Management of Pediatric Asthma. Dumitru, Catalina; Chan, Susan M. H.; Turcanu, Victor // Pediatric Drugs;2012, Vol. 14 Issue 5, p317 

    At present, the main indications for leukotriene receptor antagonists (LTRA) in pediatric asthma are as add-on therapy to inhaled corticosteroids (ICS) and as initial controller therapy in children with mild asthma, especially those who cannot or will not use ICS. LTRA are also useful for...

  • Montelukast: A Viewpoint by Romain A. Pauwels. Pauwels, R.A. // Drugs;Aug1998, Vol. 56 Issue 2, p257 

    Offers views on the leukotriene antagonist montelukast used for treating asthma. Background on asthma; Effectiveness.

  • Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Ducharme, Francine M. // BMJ: British Medical Journal (International Edition);3/22/2003, Vol. 326 Issue 7390, p621 

    Objective: To compare the safety and efficacy of anti-leukotrienes and inhaled glucocorticoids as monotherapy in people with asthma. Design: Systematic review of randomised controlled trials comparing anti-leukotrienes with inhaled glucocorticoids for 28 days or more in children and adults. Main...

  • Pharmacotherapy -- add-on therapies.  // CMAJ: Canadian Medical Association Journal;9/13/2005 Supplement, Vol. 173, pS37 

    The article focuses on the effectiveness regarding the use inhaled corticosteriods (ICS)and leukotriene receptor antagonists (LTRA)as add-on therapy in treating children with asthma. The effectiveness ICS has been compared with long-acting bronchodilators (LABA) such as salmenterol or...

  • Asthma: Montelukast vs. Inhaled Corticosteroids. Bauchner, Howard // Archives of Disease in Childhood;Apr2006, Vol. 91 Issue 4, p371 

    The article compares the effectivity of montelukast and inhaled corticosteroids (ICS) in treating patients with mild persistent asthma. The authors noted that the results in the first study have favored ICS. Aside from it, study revealed that most parents prefer to use ICS instead of leukotriene...

  • zafirlukast. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p814 

    A definition of the term "zafirlukast" is presented. It refers to a leukotriene receptor antagonist. Zafirlukast is used in asthma prevention.

  • zafirlukast.  // Taber's Cyclopedic Medical Dictionary;2005, p2367 

    The article presents a definition for the term "zafirlukast," which is a leukotriene inhibitor used for the treatment of asthma.

  • Early intervention with low-dose inhaled corticosteroid (ICS) therapy is beneficial in patients with mild persistent asthma.  // Drugs & Therapy Perspectives;Apr2008, Vol. 24 Issue 4, p9 

    Treatment of mild asthma with low-dose inhaled corticosteroids (ICSs) improves control of the disease and prevents disease exacerbation. Early treatment with ICSs appears to diminish, but not completely prevent, the decline in airway function in patients with asthma, although the positive...

  • Adrenal Insufficiency in Sepsis. Annane, Djillali // Current Pharmaceutical Design;Jul2008, Vol. 14 Issue 19, p1882 

    The role of the hypothalamic-pituitary adrenal axis in the host response to infection is crucial. The initial inflammatory response to sepsis activates the endogenous release of cortisol, which in turn modulates the synthesis and release of both pro- and anti-inflammatory mediators to restrict...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics